In RAS-mutant tumours, MEK inhibition as monotherapy has failed to demonstrate meaningful benefits largely due to the induction of feedback loops similar to those when RAF inhibitors are use in this setting[48]. This evidence concerns the gene RAF1 and neoplasm.